Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:46 AM
Ignite Modification Date:
2025-12-25 @ 3:46 AM
NCT ID:
NCT01272102
Eligibility Criteria:
Inclusion Criteria:
* Age of 40 years or older
* Diagnosed to have glaucoma by the Principal Investigator or co-investigator
* Able and willing to make the required study visits
* Able and willing to give consent and follow study instructions
Exclusion Criteria:
Ophthalmic:
* Best corrected visual acuity in either eye worse than 20/40 on a Snellen chart or on a Snellen equivalent acuity chart.
* Refractive error outside -12.00D to +8.00D spherical range or \>-3.00D cylinder.
* Previous vitreoretinal surgery in study eye.
* Vitreoretinal traction or epiretinal membrane in the study eye.
* Any active infection of anterior or posterior segments.
* Evidence of diabetic retinopathy, diabetic macular edema, or other vitreoretinal disease in the study eye upon dilated examination, or upon evaluation of retinal photos.
Systemic:
* History of diabetes, leukemia, AIDS, uncontrolled systemic hypertension, dementia or multiple sclerosis.
* A life threatening or debilitating disease.
* Participation in any study involving a non-FDA approved investigational drug (IND) within the past month, or ongoing participation in a study with a non-FDA approved or cleared investigational device (IDE).
* Current or recent (within the past 14 days) use of an agent with photosensitizing properties by any route (e.g., Visudyne®, ciprofloxacin, Bactrim®, doxycycline, etc.).
* Concomitant use of hydrochloroquine and/or chloroquine.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
40 Years
Study:
NCT01272102
Study Brief:
Protocol Section:
NCT01272102